Prostate Neoplasm Clinical Trial
Official title:
Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion
Verified date | March 2024 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study evaluates contrast-enhanced MR angiography and contrast-enhanced MR perfusion imaging for the visualization of blood vessels and enhancing tissues with better spatial detail and improved temporal fidelity compared to current methods.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | September 30, 2030 |
Est. primary completion date | September 30, 2030 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults Exclusion Criteria: - Standard exclusion criteria for clinical MRI; e.g. cardiac pacemaker, claustrophobia, an implanted device that has been determined to be MR conditional at 1.5T but not at 3T, anticipated considerable susceptibility artifact from hip prosthesis, etc.; previous rectal surgery which may preclude tolerance of an endorectal coil |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion | Assessed by comparison of two images made from the raw data set but reconstructed using the standard vs. an alternative algorithm (to be determined during study). Data will be tabulated and analyzed statistically. | Baseline (at enrollment); possible second scan at a later date |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
Completed |
NCT00255125 -
Role of Soy Supplementation in Prostate Cancer Development
|
Phase 3 | |
Terminated |
NCT02809690 -
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
|
Phase 1 | |
Completed |
NCT06020287 -
The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
|
||
Recruiting |
NCT03572946 -
Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection
|
N/A | |
Active, not recruiting |
NCT03344757 -
Health Gatherings - For Your Health After Cancer
|
N/A | |
Recruiting |
NCT05137561 -
Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy
|
N/A | |
Recruiting |
NCT04792138 -
Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
|
||
Completed |
NCT03702439 -
Prostate Cancer Screening Trial Using Imaging
|
||
Completed |
NCT04852224 -
Strength, Aging, and Memory in Prostate Cancer
|
||
Completed |
NCT01240551 -
F-18 Sodium Fluoride in Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06430411 -
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
|
||
Recruiting |
NCT02436122 -
Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT03493945 -
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
|
Phase 1/Phase 2 | |
Completed |
NCT04376008 -
A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia
|
N/A | |
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06292897 -
Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
|
||
Recruiting |
NCT03819751 -
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
|
N/A | |
Not yet recruiting |
NCT05460312 -
Protein Kinase A in Prostate Cancer Tissue.
|
||
Completed |
NCT00005916 -
PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
|
Phase 2 |